Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marie Aude Le Berre"'
Autor:
Rodrigo Resende Palhares, Glauco do Canto Britto, Yun Su, Marie-Aude Le Berre, Ricardo Saad Henriques, Fabricio Volpato Navachi, Daniela Cristina Foli Pereira, Helene Ostojic, Graziella Agostini Azevedo, Eric Van Cutsem
Publikováno v:
Revista Brasileira de Cancerologia, Vol 68, Iss 4 (2022)
Introdução: O câncer colorretal (CCR) é o segundo mais incidente e, quando metastático, apresenta taxa de sobrevida de 14% em cinco anos. Regorafenibe é um inibidor de tirosina-quinase (ITQ) aprovado para CCR metastático (CCRm) com aumento com
Externí odkaz:
https://doaj.org/article/9a28d27aaf5b4bf6b0631427abbfb0f2
Autor:
M. Luz, Mindaugas Jievaltas, Boris Alekseev, Aramis Investigators, Neal D. Shore, Toni Sarapohja, Sergey Polyakov, Iris Kuss, Karim Fizazi, Matthew R. Smith, Teuvo L Tammela, Marie-Aude Le Berre, Egils Vjaters, Amir Snapir, Oana Petrenciuc, Albertas Ulys
Publikováno v:
New England Journal of Medicine. 383:1040-1049
Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b560a14cdb95f452333c21d1df05938
https://doi.org/10.1056/nejmoa2001342
https://doi.org/10.1056/nejmoa2001342
Autor:
Martin Bögemann, Neal D. Shore, Matthew R. Smith, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Thierry Lebret, Martin Schostak, Frank Verholen, Marie-Aude Le Berre, Shankar Srinivasan, Jorge Ortiz, Ateesha F. Mohamed, Toni Sarapohja, Karim Fizazi
Publikováno v:
European urology, Amsterdam : Elsevier B.V., 2023, vol. 83, iss. 3, p. 212-221
Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have a high risk of progression to metastatic disease, particularly if their prostate-specific antigen doubling time (PSADT) is ≤6 mo. However, patients remain at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b5b416d27420ef8e9925225f89d480
https://repository.vu.lt/VU:ELABAPDB153215389&prefLang=en_US
https://repository.vu.lt/VU:ELABAPDB153215389&prefLang=en_US
Autor:
Martin Bögemann, Neal D. Shore, Matthew R. Smith, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Thierry Lebret, Martin Schostak, Frank Verholen, Marie-Aude Le Berre, Shankar Srinivasan, Jorge Ortiz, Ateesha F. Mohamed, Toni Sarapohja, Karim Fizazi
Publikováno v:
European Urology. 83:e60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2930ad9fc8e8c29f23af175a7111900a
https://doi.org/10.1016/j.eururo.2022.11.018
https://doi.org/10.1016/j.eururo.2022.11.018
Autor:
Toni Sarapohja, Matthew R. Smith, Albertas Ulys, Ateesha F. Mohamed, Egils Vjaters, Sergey Polyakov, Amir Snapir, Dawn Odom, Iris Kuss, Neal D. Shore, Mindaugas Jievaltas, Murilo Luz, Marie Aude Le Berre, Karim Fizazi, Teuvo L.J. Tammela, Jennifer Bartsch, Boris Alekseev
Publikováno v:
European journal of cancer (Oxford, England : 1990). 154
Background: In the ARAMIS trial, darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT significantly improved metastasis-free survival (MFS), overall survival (OS) and time to pain progression in patients with non-metastatic ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2f52eac8f8bb4d4ef64180f4eccdf4
https://pubmed.ncbi.nlm.nih.gov/34273811
https://pubmed.ncbi.nlm.nih.gov/34273811
Autor:
Toni Sarapohja, Neal D. Shore, Mutsushi Kawakita, Hiroya Mizusawa, Marie Aude Le Berre, Matthew R. Smith, Kazuhiro Suzuki, Masahiro Iinuma, Tetsuo Momma, Mototsugu Oya, Kazuki Kobayashi, Teuvo L.J. Tammela, Hiroji Uemura, Amir Snapir, Hirotsugu Uemura, Satoshi Fukasawa, Hisashi Matsushima, Nobuaki Matsubara, Iris Kuss, Ken-ichi Tabata, Tadahiro Kobayashi, Karim Fizazi, Hiroaki Nishimatsu
Publikováno v:
International Journal of Clinical Oncology
Background Darolutamide, an oral androgen receptor inhibitor, has been approved for treating nonmetastatic castration-resistant prostate cancer (nmCRPC), based on significant improvements in metastasis-free survival (MFS) in the ARAMIS clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e6518b45933ebb3931b0d705c800ab1
https://trepo.tuni.fi/handle/10024/128183
https://trepo.tuni.fi/handle/10024/128183
Autor:
Neal D. Shore, Matthew R. Smith, Toni Sarapohja, Boris Alekseev, Iris Kuss, Amir Snapir, Marie-Aude Le Berre, Albertas Ulys, Mindaugas Jievaltas, Sergey Polyakov, T Tammela, Murilo Luz, Egils Vjaters, Karim Fizazi
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:Asymptomatic nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients (pts) would benefit from treatments (Tx) that delay disease progression with minimal Tx-r...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2df61922c24316a595456b1a75a35388
https://doi.org/10.1097/01.ju.0000557501.15711.19
https://doi.org/10.1097/01.ju.0000557501.15711.19
Autor:
Shankar Srinivasan, Marie-Aude Le Berre, Teuvo L.J. Tammela, Karim Fizazi, Matthew R. Smith, Christopher Michael Pieczonka, Christian Zurth, Oana Petrenciuc, David L. Morris, Iris Kuss, Jeanny B. Aragon-Ching, Neal D. Shore
Publikováno v:
Journal of Clinical Oncology. 39:5079-5079
5079 Background: Patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) need therapy that prolongs survival with little added toxicity, thus preserving quality of life. The second-generation androgen receptor inhibitors (ARIs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::248864529c7b125bf5c2d7939fca5eb2
https://doi.org/10.1200/jco.2021.39.15_suppl.5079
https://doi.org/10.1200/jco.2021.39.15_suppl.5079
Autor:
Adriano Paula, Matthew R. Smith, Urban Emmenegger, Diana Sofia Aleman Polanco, Teuvo L.J. Tammela, Karim Fizazi, Glauco Costa Silveira, Raoul S. Concepcion, Martin Eduardo Richardet, Felipe Melo Cruz, Gustavo Borghesi, Marie-Aude Le Berre, Neal D. Shore, Iris Kuss, Neil Fleshner, Luke T. Nordquist, Toni Sarapohja, Carlos Augusto de Mendonça Beato
Publikováno v:
Journal of Clinical Oncology. 39:239-239
239 Background: DARO is a structurally distinct androgen receptor inhibitor (ARI) approved for treating nmCRPC. In ARAMIS, DARO significantly reduced the risk of death by 31% (HR = 0.69; 95% CI: 0.53-0.88; p = 0.003) and prolonged median metastasis-f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76c6861e91092e3a47c24787b601901e
https://doi.org/10.1200/jco.2021.39.6_suppl.239
https://doi.org/10.1200/jco.2021.39.6_suppl.239
Autor:
Karim Fizazi, Marie-Aude Le Berre, Amir Snapir, T Tammela, Oana Petrenciuc, Albertas Ulys, Toni Sarapohja, Matthew R. Smith, Neal D. Shore, Murilo Luz, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Iris Kuss, Boris Alekseev
Publikováno v:
Journal of Clinical Oncology. 38:5514-5514
5514 Background: DARO is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men with nmCRPC after demonstrating significantly prolonged metastasis-free survival, compared with placebo (PBO), in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fdac5dd6d1c5b3ff4ae3a0151c858b6
https://doi.org/10.1200/jco.2020.38.15_suppl.5514
https://doi.org/10.1200/jco.2020.38.15_suppl.5514